Immuneering Corporation (IMRX) News
Track canonical SquawkNews coverage tagged to IMRX, Immuneering Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Immuneering to Present at the ESMO Congress 2026
Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation NASDAQ
GEOPOLITICS | Sep 24, 2026, 11:32 AM UTC
H
IMRX - Immuneering to Present at the ESMO Congress 2026
IMRX - Immuneering to Present at the ESMO Congress 2026
GEOPOLITICS | Sep 24, 2026, 11:30 AM UTC
L
IMRX: Atebimetinib shows 17.3 months median OS in first-line pancreatic cancer with improved tolerability
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with strong phase II data showing 17.3 months median OS and improved tolerability. The drug's unique mechanism addresses prior MEK inhibit
NEWS | Sep 14, 2026, 10:13 PM UTC
L
IMRX: Atebimetinib shows best-in-class survival and tolerability in first-line pancreatic cancer trials
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with phase II data showing a median OS of 17.3 months and strong tolerability. The drug's unique mechanism and reduced toxicity differenti
NEWS | Sep 14, 2026, 09:51 PM UTC
L
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months -- New analyses evaluate the overall survival implic
EQUITY | Sep 10, 2026, 11:32 AM UTC
L
IMRX - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
IMRX - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
Immuneering management plans to attend upcoming investor conferences
Immuneering Corporation (IMRX) said management plans to participate in upcoming investor conferences, with further details to follow.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
IMRX - Immuneering to Participate in Upcoming Investor Conferences
IMRX - Immuneering to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 08:05 PM UTC
L
IMRX - Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - C
IMRX - Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
REGULATION | Aug 26, 2026, 09:16 PM UTC
L
IMRX - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
IMRX - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
EARNINGS | Aug 05, 2026, 11:30 AM UTC
L
IMRX - PR: Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS
IMRX - PR: Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition Link To Press Release
EQUITY | Jul 21, 2026, 08:15 PM UTC